Magstim

Founded in 1992, Magstim is a pioneering private company in the neurotechnology and medical device sector, with a 30+ year history. It operates a commercial-stage business model, generating revenue from the sale of its TMS, EEG, and tDCS systems to research institutions and clinical providers globally. The company's technology is clinically validated, with its TMS systems forming the basis for FDA-cleared treatments for conditions like Major Depressive Disorder (MDD). Magstim's strategy focuses on expanding clinical indications for its neuromodulation platforms and integrating its modalities for advanced brain research and therapy.

Integrated neuromodulation and neuroimaging platform featuring Transcranial Magnetic Stimulation (TMS), high-density Electroencephalography (EEG) via EGI systems, and Transcranial Direct Current Stimulation (tDCS). Focus on precision magnetic stimulation and multi-modal integration (e.g., TMS-EEG) for research and therapy.

Magstim competes in the neurotechnology space against other medical device companies specializing in TMS (e.g., Neuronetics, BrainsWay), EEG systems (e.g., ANT Neuro, Brain Products, Natus), and tDCS devices. Its key differentiators are its long history, strong scientific reputation, clinical validation, and integrated multi-modal approach. Competition is based on technological features, clinical efficacy data, price, and global service and support networks.